Managing  	Managing  	 VBG	B-NP
hyponatremia  	hyponatremia  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
heart  	heart  	 NN	B-NP
failure  	failure  	 NN	I-NP
Approximately  	Approximately  	 RB	O
20 	20 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
heart  	heart  	 NN	B-NP
failure  	failure  	 NN	I-NP
patients  	patients  	 NNS	I-NP
have  	have  	 VBP	O
low  	low  	 JJ	O
levels  	levels  	 NNS	O
of  	of  	 IN	O
serum  	serum  	 JJ	B-NP
sodium 	sodium 	 NN	I-NP
,  	,  	 ,	O
often  	often  	 RB	O
at  	at  	 IN	O
a  	a  	 DT	O
time  	time  	 NN	O
when  	when  	 WRB	O
they  	they  	 PRP	O
are  	are  	 VBP	O
hospitalized  	hospitalized  	 VBN	O
during  	during  	 IN	O
a  	a  	 DT	O
period  	period  	 NN	O
of  	of  	 IN	O
decompensation 	decompensation 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
presence  	presence  	 NN	O
of  	of  	 IN	O
hyponatremia  	hyponatremia  	 JJ	O
adversely  	adversely  	 NN	O
affects  	affects  	 VBZ	O
outcomes  	outcomes  	 VBN	O
in  	in  	 IN	O
heart  	heart  	 NN	B-NP
failure  	failure  	 NN	I-NP
and  	and  	 CC	O
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
impaired  	impaired  	 JJ	O
cognitive  	cognitive  	 NN	B-NP
and  	and  	 CC	O
neuromuscular  	neuromuscular  	 JJ	B-NP
function 	function 	 NN	I-NP
.  	.  	 .	O
Current  	Current  	 JJ	B-NP
strategies  	strategies  	 NNS	I-NP
for  	for  	 IN	I-NP
treating  	treating  	 VBG	I-NP
hyponatremia  	hyponatremia  	 NN	I-NP
in  	in  	 IN	O
heart  	heart  	 NN	B-NP
failure  	failure  	 NN	I-NP
patients  	patients  	 NNS	I-NP
have  	have  	 VBP	O
limited  	limited  	 JJ	O
efficacy 	efficacy 	 NN	O
.  	.  	 .	O
Although  	Although  	 IN	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
hyponatremia  	hyponatremia  	 NN	B-NP
in  	in  	 IN	O
heart  	heart  	 NN	B-NP
failure  	failure  	 NN	I-NP
patients  	patients  	 NNS	I-NP
is  	is  	 VBZ	O
polyfactorial 	polyfactorial 	 VBN	O
,  	,  	 ,	O
the  	the  	 DT	O
nonosmotic  	nonosmotic  	 JJ	B-NP
release  	release  	 NN	I-NP
of  	of  	 IN	I-NP
arginine  	arginine  	 JJ	I-NP
vasopressin  	vasopressin  	 NNS	I-NP
( 	( 	 -LRB-	O
AVP 	AVP 	 NNP	B-NP
)  	)  	 -RRB-	O
from  	from  	 IN	O
the  	the  	 DT	O
posterior  	posterior  	 JJ	O
pituitary  	pituitary  	 NN	O
plays  	plays  	 VBZ	O
a  	a  	 DT	O
dominant  	dominant  	 JJ	O
role  	role  	 NN	O
in  	in  	 IN	O
this  	this  	 DT	O
process  	process  	 NN	O
through  	through  	 IN	O
its  	its  	 PRP$	O
effects  	effects  	 NNS	O
on  	on  	 IN	O
regulating  	regulating  	 VBG	O
the  	the  	 DT	O
absorption  	absorption  	 NN	O
of  	of  	 IN	O
free  	free  	 JJ	O
water  	water  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
distal  	distal  	 JJ	B-NP
portion  	portion  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
nephron 	nephron 	 NN	I-NP
.  	.  	 .	O
Drugs  	Drugs  	 NNS	O
which  	which  	 WDT	O
block  	block  	 VBP	O
the  	the  	 DT	O
effects  	effects  	 NNS	O
of  	of  	 IN	O
AVP  	AVP  	 NNP	B-NP
on  	on  	 IN	O
the  	the  	 DT	O
V2  	V2  	 CD	B-NP
receptor  	receptor  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
shown  	shown  	 VBN	O
to  	to  	 TO	O
increase  	increase  	 VB	O
serum  	serum  	 JJ	B-NP
sodium  	sodium  	 NN	I-NP
by  	by  	 IN	O
promoting  	promoting  	 VBG	O
the  	the  	 DT	O
excretion  	excretion  	 NN	B-NP
of  	of  	 IN	O
free  	free  	 JJ	O
water  	water  	 NN	O
from  	from  	 IN	O
the  	the  	 DT	O
kidney 	kidney 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
review 	review 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
theoretical  	theoretical  	 JJ	B-NP
basis  	basis  	 NN	I-NP
supporting  	supporting  	 VBG	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
AVP  	AVP  	 NNP	B-NP
blockers  	blockers  	 NN	I-NP
is  	is  	 VBZ	O
discussed  	discussed  	 VBN	O
and  	and  	 CC	O
results  	results  	 NNS	O
from  	from  	 IN	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
in  	in  	 IN	O
which  	which  	 WDT	O
they  	they  	 PRP	O
were  	were  	 VBD	O
administered  	administered  	 VBN	O
to  	to  	 TO	O
euvolemic  	euvolemic  	 VB	O
and  	and  	 CC	O
hypervolemic  	hypervolemic  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
are  	are  	 VBP	O
reviewed 	reviewed 	 VBN	O
.  	.  	 .	O
Administration  	Administration  	 NN	B-NP
of  	of  	 IN	I-NP
AVP  	AVP  	 NNP	I-NP
blockers  	blockers  	 VBD	O
to  	to  	 TO	O
heart  	heart  	 NN	B-NP
failure  	failure  	 NN	I-NP
patients  	patients  	 NNS	I-NP
increases  	increases  	 VBZ	O
free  	free  	 JJ	O
water  	water  	 NN	B-NP
excretion 	excretion 	 NN	I-NP
,  	,  	 ,	O
promotes  	promotes  	 JJ	O
weight  	weight  	 NN	B-NP
loss 	loss 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
increases  	increases  	 NNS	O
serum  	serum  	 VBP	B-NP
sodium  	sodium  	 JJ	I-NP
levels  	levels  	 NNS	I-NP
without  	without  	 IN	O
significant  	significant  	 JJ	O
major  	major  	 JJ	O
adverse  	adverse  	 JJ	O
effects 	effects 	 NNS	O
.  	.  	 .	O
Clinical  	Clinical  	 JJ	B-NP
trial  	trial  	 NN	I-NP
results  	results  	 NNS	I-NP
demonstrate  	demonstrate  	 VBP	O
safety  	safety  	 NN	O
during  	during  	 IN	O
long-term  	long-term  	 JJ	O
administration 	administration 	 NN	B-NP
.  	.  	 .	O
These  	These  	 DT	O
findings  	findings  	 NNS	O
indicate  	indicate  	 VBP	O
that  	that  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
AVP  	AVP  	 NNP	B-NP
receptor  	receptor  	 NN	I-NP
antagonists  	antagonists  	 NNS	I-NP
should  	should  	 MD	O
be  	be  	 VB	O
considered  	considered  	 VBN	O
in  	in  	 IN	O
heart  	heart  	 NN	B-NP
failure  	failure  	 NN	I-NP
patients  	patients  	 NNS	I-NP
who  	who  	 WP	O
have  	have  	 VBP	O
evidence  	evidence  	 NN	O
of  	of  	 IN	O
significant  	significant  	 JJ	O
hyponatremia 	hyponatremia 	 NN	B-NP
.  	.  	 .	O
